Telix Pharmaceuticals Q3 Revenue Rises 19% to $245 Million, Reaffirms FY2026 Guidance

Telix Pharmaceuticals Ltd. (TLX) reported a 19% increase in third-quarter group revenue to $245 million from $206 million a year earlier, and reaffirmed its full-year 2026 revenue guidance of $950 million to $970 million, saying revenue is tracking toward the upper end of the range. Precision Medicine revenue rose 30% to $201 million from $155 million, driven by the prostate cancer imaging agents Gozellix and Illuccix, the company said. Operational highlights for the quarter ended September 30, 2026, included the first commercial doses of recently approved Pixclara for glioma imaging, administered in September 2026, and completed enrollment in the Phase III BiPASS study evaluating pre-biopsy prostate cancer detection. TLX closed Tuesday's trade at $11.16, up 3.91%, within a 52-week range of $6.28 to $13.11. The stock was up 0.81% at $11.25 in overnight trading.